These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors. Pontow S; Ratner L J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632 [TBL] [Abstract][Full Text] [Related]
5. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins. Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061 [TBL] [Abstract][Full Text] [Related]
6. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408 [TBL] [Abstract][Full Text] [Related]
7. An extended CCR5 ECL2 peptide forms a helix that binds HIV-1 gp120 through non-specific hydrophobic interactions. Abayev M; Moseri A; Tchaicheeyan O; Kessler N; Arshava B; Naider F; Scherf T; Anglister J FEBS J; 2015 May; 282(10):1906-1921. PubMed ID: 25703038 [TBL] [Abstract][Full Text] [Related]
8. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction. Hatse S; Bridger G; de Clercq E; Schols D Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074 [TBL] [Abstract][Full Text] [Related]
9. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651 [TBL] [Abstract][Full Text] [Related]
11. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL)20, and CCL21. Badr G; Borhis G; Treton D; Moog C; Garraud O; Richard Y J Immunol; 2005 Jul; 175(1):302-10. PubMed ID: 15972662 [TBL] [Abstract][Full Text] [Related]
12. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller. Chevigne A; Delhalle S; Counson M; Beaupain N; Rybicki A; Verschueren C; Staub T; Schmit JC; Seguin-Devaux C; Deroo S AIDS; 2016 Jan; 30(3):377-82. PubMed ID: 26760231 [TBL] [Abstract][Full Text] [Related]
13. CCR5 N-terminus peptides enhance X4 HIV-1 infection by CXCR4 up-regulation. Dettin M; Zanchetta M; Pasquato A; Borrello M; Piatier-Tonneau D; Di Bello C; De Rossi A Biochem Biophys Res Commun; 2003 Aug; 307(3):640-6. PubMed ID: 12893271 [TBL] [Abstract][Full Text] [Related]
14. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. Tanaka R; Yoshida A; Murakami T; Baba E; Lichtenfeld J; Omori T; Kimura T; Tsurutani N; Fujii N; Wang ZX; Peiper SC; Yamamoto N; Tanaka Y J Virol; 2001 Dec; 75(23):11534-43. PubMed ID: 11689635 [TBL] [Abstract][Full Text] [Related]
15. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. Brelot A; Heveker N; Montes M; Alizon M J Biol Chem; 2000 Aug; 275(31):23736-44. PubMed ID: 10825158 [TBL] [Abstract][Full Text] [Related]
16. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Mondor I; Moulard M; Ugolini S; Klasse PJ; Hoxie J; Amara A; Delaunay T; Wyatt R; Sodroski J; Sattentau QJ Virology; 1998 Sep; 248(2):394-405. PubMed ID: 9721247 [TBL] [Abstract][Full Text] [Related]
17. Emergence, dominance, and possible decline of CXCR4 chemokine receptor usage during the course of HIV infection. Meehan CJ; Hedge JA; Robertson DL; McCormack GP; Travers SA J Med Virol; 2010 Dec; 82(12):2004-12. PubMed ID: 20981786 [TBL] [Abstract][Full Text] [Related]
18. Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4. Antonsson L; Boketoft A; Garzino-Demo A; Olde B; Owman C AIDS; 2003 Dec; 17(18):2571-9. PubMed ID: 14685051 [TBL] [Abstract][Full Text] [Related]
19. CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. Gouwy M; Struyf S; Berghmans N; Vanormelingen C; Schols D; Van Damme J Eur J Immunol; 2011 Apr; 41(4):963-73. PubMed ID: 21381021 [TBL] [Abstract][Full Text] [Related]
20. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4. Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]